<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02052921</url>
  </required_header>
  <id_info>
    <org_study_id>NP172/11</org_study_id>
    <nct_id>NCT02052921</nct_id>
  </id_info>
  <brief_title>Observation Versus Surgical Resection in Patients With Rectal Cancer Who Achieved Complete Clinical Response After Neoadjuvant Chemoradiotherapy</brief_title>
  <official_title>Open Randomized Study of Observation Versus Surgical Resection in Patients With Rectal Cancer Who Achieved Complete Clinical Response After Neoadjuvant Chemoradiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto do Cancer do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto do Cancer do Estado de São Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      With the possibility of pathological complete response in surgical specimens, some authors&#xD;
      have proposed non-operative management of the patient group, when re-staged after neoadjuvant&#xD;
      treatment, have complete clinical response. So far, this approach remains discussed in the&#xD;
      literature, and there are still many uncertainties that patients with clinical complete&#xD;
      response after chemoradiotherapy in fact no detectable viable tumor and may be omitted of&#xD;
      radical surgical treatment. It is a still investigational approach and actually gained space&#xD;
      even for patients with very high or who refuse surgery after all clarifications surgical&#xD;
      risk.&#xD;
&#xD;
      Hypothesis: The preservation of the rectum in patients with adenocarcinoma of the middle and&#xD;
      distal rectum (up to 10 cm) reaching clinical complete response after neoadjuvant&#xD;
      chemoradiotherapy have similar rate of the rectal cancer recurrence than patients who&#xD;
      underwent surgical rectal resection.&#xD;
&#xD;
      This will be a prospective, randomized, open label phase II of surgical resection versus&#xD;
      conservative treatment (observation) in patients with mid and distal rectal cancer who&#xD;
      achieved complete after neoadjuvant chemoradiotherapy combined with clinical response.&#xD;
&#xD;
      The main objective of this study is to assess whether conservative approach is similar to&#xD;
      rectosigmoidectomy with complete mesorectal excision or amputation abdminoperineal the rectum&#xD;
      in patients with complete clinical response after neoadjuvant therapy combined&#xD;
      chemoradiotherapy.&#xD;
&#xD;
      Patient Selection: To be eligible patients who have neoadjuvant prior histologic diagnosis of&#xD;
      rectal adenocarcinoma, tumors located within 10 cm from the anal verge, a complete clinical&#xD;
      response after treatment with chemoradiotherapy for rectal tumors staged clinical and&#xD;
      radiological T3-4 N0 M0 or T (any) N + M0, absence of colorectal synchronous tumors.&#xD;
&#xD;
      Treatment: Eligible patients will be randomized 1:1 to resection of the rectum or notice. The&#xD;
      period for randomization of patients will be 12 weeks after the last dose of radiotherapy /&#xD;
      chemotherapy, so that we can properly assess the antitumor response as described above. After&#xD;
      randomization, patients in the surgical group will undergo resection of the rectum with&#xD;
      complete excision of mesorectal within 2 weeks after randomization.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    During the execution time foreseen in the project, the expected number of patients was not&#xD;
    reached.&#xD;
  </why_stopped>
  <start_date type="Actual">November 2011</start_date>
  <completion_date type="Actual">April 23, 2020</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Operative complication rate</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Presence of viable tumor in the surgical specimen</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pattern of recurrence</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Rectal resection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Surgical rectal resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conservative approach</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Rectal resection</intervention_name>
    <description>Surgical rectal resection</description>
    <arm_group_label>Rectal resection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation</intervention_name>
    <arm_group_label>Observation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological diagnosis of rectal adenocarcinoma&#xD;
&#xD;
          -  tumors located within 10 cm from the anal verge by rigid proctoscopy measurement&#xD;
&#xD;
          -  Complete clinical response after neoadjuvant treatment with chemoradiotherapy for&#xD;
             rectal tumors clinical and radiologically staged as T3-4 N0 M0 or T (any) N + M0&#xD;
&#xD;
          -  Absence of colorectal synchronous tumors&#xD;
&#xD;
          -  Age between 18 and 75 years&#xD;
&#xD;
          -  ECOG performance scale ≤ 2,&#xD;
&#xD;
          -  last dose of chemotherapy / radiation therapy in up to 12 weeks&#xD;
&#xD;
          -  Good organic function&#xD;
&#xD;
          -  Absence of serious comorbidities defined by the doctor to prevent surgical resection&#xD;
             of the rectum and / or neoadjuvant therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Comorbidities clinically significant where surgical resection and / or neoadjuvant&#xD;
             therapy is impossible, according to medical assessment.&#xD;
&#xD;
          -  Prior antineoplastic therapy different from neoadjuvant therapy.&#xD;
&#xD;
          -  History of Crohn's disease or ulcerative colitis.&#xD;
&#xD;
          -  Confirmation or strongly suspected inherited polyp syndrome.&#xD;
&#xD;
          -  Pregnant women or during lactation (women of childbearing age should have a negative&#xD;
             pregnancy test).&#xD;
&#xD;
          -  Concurrent participation in another research protocol involving therapeutic&#xD;
             intervention.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivan Cecconello, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculdade de Medicina da USP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulysses Ribeiro, MD</last_name>
    <role>Study Director</role>
    <affiliation>Instituto do Câncer do Estado de São Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Do Câncer Do Estado de São Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01246-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 31, 2014</study_first_submitted>
  <study_first_submitted_qc>January 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2014</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Observation</keyword>
  <keyword>Rectal Resection</keyword>
  <keyword>complete clinical response</keyword>
  <keyword>neoadjuvant chemoradiotherapy.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

